Sign in to view content

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study

Charles C Wykoff, MD, PhD, FASRS

Video
Published 2024

Related

MCO-010 Optogenetic Therapy for Severe Vision Loss in Stargardt Disease: 6-Month Outcomes From the Phase 2 STARLIGHT Trial
Allen C Ho, MD FASRS
Annual Meeting Talks
2023
Phase 1/2 Clinical Trial of Intravitreal 4D-125 AAV Gene Therapy in Patients with Advanced XLRP: Interim Safety & Preliminary Activity
Cagri G Besirli, MD, PhD, FASRS
Updates from the Field
2021
Gene Therapy in Pediatric Retina Patients at the Bascom Palmer Eye Institute: What I Have Learned
Audina M. Berrocal, MD FASRS
Annual Meeting Talks
2019

Category: AMD-Neovascular

See more